Search

Brian Leedman

Brian Leedman is an investor relations and capital raising professional in the biotechnology industry with a background in senior marketing roles at Ernst & Young and Westpac Bank. Mr Leedman served for 10 years as the Vice President, Investor Relations for Nasdaq/ASX listed, pSivida Corp. In 2013, he co-founded two new biotechnology companies that have listed on the ASX and is involved in promoting the sector through his role as chairman (WA) of Ausbiotech, the association of biotechnology companies in Australia. Mr Leedman holds a Bachelor of Economics and a Master of Business Administration from the University of Western Australia where he also served for two years as President of the Graduate Management Association. He is the non-executive director of Paynes Find Gold and a board member of the Australia Israel Chamber of Commerce and Heritage Perth. He is an active speaker on the conference circuit and has chaired a number of national investor relations and capital raising conferences in Sydney and Perth.
Bio last updated 17 Nov 2018

Access to our data for Brian Leedman is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Brian Leedman is linked to 8 organisations which are included in 2 lists - Technology Companies and Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 31/10/18

1 year TSR5 year TSR
92ndResApp Health55%75%
149thPeppermint Innovation33%-16%
224thAssembleBay18%-40%
447thZelda Therapeutics-16%65%
744 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Roles

2016
Co-Founder; Vice President, Corporate Affairs
Year started and most recent title

Revenue

157th↑AssembleBay$1.0m
158th-Cre8tek$1.0m
159th↑ResApp Health$999k
160th↑Zelda Therapeutics$960k
161st↓Peppermint Innovation$908k
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer